5-substituted thiazol-2-ylamino compounds as protein kinase inhibitors and compositions

The present invention provides a compound of formula I [Formula 1] In 5-substituted thiazol-2-ylamino compounds represented, such pharmaceutical compositions comprising the compounds and abnormal or deregulated kinase activity associated with a disease or disorder, particularly Abl, Aurora-A, Bcr-Abl, bmx, CDK1 / cyclin B, CHK2, Fes, FGFR3, Flt3, GSK3β, JNK1α1, provides for the use of such compounds in the treatment or prevention of Lck, MKK4 and diseases or disorders in which aberrant activation of TrkB kinases are involved .